Moderna, Inc. Common Stock
Here’s whether Moderna, Inc. Common Stock (MRNA) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Neutral.
Positives: trading above the 200-day MA (long-term uptrend intact); 50-day MA is rising (+4.61% over 10 days); strong 1-year return of +59.0%; 3-month momentum positive (+6.6%). Concerns: below the 50-day MA (medium-term momentum negative); RSI 12 — oversold; declining volume on rally — weak conviction (0.59x 30d avg). Currently 36.8% off its 52-week high. Score: +2/7.
MRNA is holding above its long-term 200-day MA ($44.14) but has slipped below the 50-day MA ($57.70), pointing to short-term weakness in an otherwise intact trend. An RSI of 11.6 has dropped into oversold territory, which has historically preceded short-term bounces. The 1-year return of +59.0% compares to +16.5% for SPY (beat the market by 42.5%). The current 36.8% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.